Monocyte chemoattractant protein 1 (MCP1/CCL2) and CCL4 production are linked to unfavorable prognosis [74,75] and monocyte recruitment from the periphery [76], and we have observed a decrease of these targets in plasma-treated PDA. The gene discussed is CCL2; the disease is Patent ductus arteriosus.